NCT06095674View on ClinicalTrials.gov

ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Cervical Cancer
Interventions
DRUG

Anti-PD-1 antibody balstilimab

Both antibodies will be neoadjuvantly administered around the cervical tumor.

Trial Locations (1)

Unknown

Amsterdam UMC, Amsterdam

Sponsors

Collaborators (1)

Agenus Inc.
All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

collaborator

Agenus Inc.

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER